Viking Therapeutics, Inc. VKTX
35.56
(1.19)
(3.24%)
as of 25 Sep
- Market cap
- $4.3B
- P/E
- 0.0×
Follow VKTX
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (88.85%) | (70.04%) | (47.34%) | (29.23%) |
+8 more TTM periods Free account |
|
| (79.24%) | (64.04%) | (44.29%) | (28.31%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(131.11%) | (94.11%) | (56.29%) | (33.31%) | |
Free Cash Flow per Share |
(3.60) | (2.94) | (2.47) | (2.00) | |
Free Cash Flow |
(418.44) | (340.33) | (278.68) | (224.58) | |
| Other line items | |||||
Cash ROIC |
(45.98%) | (30.80%) | (20.72%) | (15.73%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.78 | 0.72 | 0.77 | 0.95 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.60) | (2.94) | (2.47) | (2.00) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates